{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:32:37Z","timestamp":1793730757898,"version":"4.6.1"},"reference-count":30,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>The American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists have recently published revised guidelines for the therapeutic monitoring of vancomycin. Previous iterations of the guideline largely focused on targeting vancomycin trough concentrations (VTCs) in the range of 15 to 20 mg\/L for therapeutic efficacy. The revised guidelines shift the focus of therapeutic monitoring directly to AUC\/MIC-based therapeutic monitoring for children, with a suggestion of a goal AUC\/MIC 400 to 800. The primary hesitation in applying these recommendations to children stems from the absence of pediatric clinical data demonstrating correlations with clinical outcomes and either VTC or AUC and no benefit in other secondary outcomes (e.g., recurrence, duration of bacteremia). One can glean indirectly from this that such aggressive dosing and monitoring strategies are unnecessary to achieve therapeutic success in the majority of children with serious methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections. Providers should carefully weigh the potential unknown benefits of targeting vancomycin AUC 400 to 800 mg*hr\/L in children with the known risks of acute kidney injury associated with increasing the dose of vancomycin as well as the substantial time, effort, and costs of this process.<\/jats:p>","DOI":"10.5863\/1551-6776-25.6.472","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T15:06:28Z","timestamp":1597417588000},"page":"472-475","source":"Crossref","is-referenced-by-count":4,"title":["Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges"],"prefix":"10.5863","volume":"25","author":[{"given":"J. Chase","family":"McNeil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon L.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"11","key":"i1551-6776-25-6-472-b1","series-title":"Am J Health Syst Pharm","first-page":"835","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","year":"2020","unstructured":"Rybak\n              MJ\n            , LeJ, LodiseTP, \n          et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11): 835\u2013864."},{"issue":"11","key":"i1551-6776-25-6-472-b2","series-title":"Pharmacotherapy","first-page":"1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","year":"2009","unstructured":"Rybak\n              MJ\n            , LomaestroBM, RotschaferJC, \n          et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275\u20131279."},{"issue":"3","key":"i1551-6776-25-6-472-b3","series-title":"J Pediatric Infect Dis Soc","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jpids\/pit032","article-title":"Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections","volume":"2","year":"2013","unstructured":"Chhim\n              RF\n            , ArnoldSR, LeeKR.\n          Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc. 2013;2(3):292. doi:10.1093\/jpids\/pit032"},{"issue":"10","key":"i1551-6776-25-6-472-b4","series-title":"Pediatr Infect Dis J","first-page":"1077","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections","volume":"32","year":"2013","unstructured":"Frymoyer\n              A\n            , GuglielmoBJ, HershAL.\n          Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077\u20131079."},{"issue":"5","key":"i1551-6776-25-6-472-b5","series-title":"Pediatr Infect Dis J","first-page":"398","article-title":"Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate","volume":"28","year":"2009","unstructured":"Frymoyer\n              A\n            , HershAL, BenetLZ, GuglielmoBJ.\n          Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398\u2013402."},{"issue":"4","key":"i1551-6776-25-6-472-b6","series-title":"Pediatr Infect Dis J","first-page":"e155","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","year":"2013","unstructured":"Le\n              J\n            , BradleyJS, MurrayW, \n          et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155\u2013e163."},{"issue":"2","key":"i1551-6776-25-6-472-b7","series-title":"Paediatr Drugs","first-page":"153","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review","volume":"20","year":"2018","unstructured":"Tkachuk\n              S\n            , CollinsK, EnsomMHH.\n          The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review. Paediatr Drugs. 2018;20(2):153\u2013164."},{"issue":"5","key":"i1551-6776-25-6-472-b8","series-title":"Ther Drug Monit","first-page":"619","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","year":"2015","unstructured":"Hahn\n              A\n            , FrenckRW> Jr, Allen-StaatM, \n          et al. Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u2013625."},{"issue":"4","key":"i1551-6776-25-6-472-b9","series-title":"J Pediatr Pharmacol Ther","first-page":"312","article-title":"Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"24","year":"2019","unstructured":"Regen\n              RB\n            , SchumanSS, ChhimRF, \n          et al. Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia. J Pediatr Pharmacol Ther. 2019;24(4):312\u2013319."},{"issue":"8","key":"i1551-6776-25-6-472-b10","series-title":"Clin Infect Dis","first-page":"1536","article-title":"The Emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","year":"2020","unstructured":"Lodise\n              TP\n            , RosenkranzSL, FinnemeyerM, \n          et al. The Emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536\u20131545."},{"issue":"2","key":"i1551-6776-25-6-472-b11","series-title":"J Pediatric Infect Dis Soc.","first-page":"127","article-title":"Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?","volume":"3","year":"2014","unstructured":"Knoderer\n              CA\n            , NicholsKR, LyonKC, VeverkaMM, WilsonAC.\n          Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?\n          J Pediatric Infect Dis Soc.\n          2014;3(2):127\u2013131."},{"issue":"11","key":"i1551-6776-25-6-472-b12","series-title":"Clin Infect Dis","first-page":"1955","article-title":"Clinical and micro-biologic variables predictive of orthopedic complications following S. aureus acute hematogenous osteoarticular infections in children","volume":"69","year":"2019","unstructured":"McNeil\n              JC\n            , VallejoJG, KokEY, \n          et al. Clinical and micro-biologic variables predictive of orthopedic complications following S. aureus acute hematogenous osteoarticular infections in children. Clin Infect Dis. 2019;69(11):1955\u20131961."},{"issue":"13","key":"i1551-6776-25-6-472-b13","series-title":"JAMA","first-page":"1330","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","year":"2014","unstructured":"Holland\n              TL\n            , ArnoldC, FowlerVGJr.\n          Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312(13):1330\u20131341."},{"issue":"4","key":"i1551-6776-25-6-472-b14","series-title":"J Pediatric Infect Dis Soc","first-page":"338","article-title":"Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"7","year":"2018","unstructured":"Hsu\n              AJ\n            , HamdyRF, HuangY, \n          et al. Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus bacteremia in children. J Pediatric Infect Dis Soc. 2018;7(4):338\u2013341."},{"issue":"3","key":"i1551-6776-25-6-472-b15","series-title":"Pediatr Infect Dis J.","first-page":"263","article-title":"Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome","volume":"35","year":"2016","unstructured":"McNeil\n              JC\n            , KokEY, ForbesAR, \n          et al. Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome. Pediatr Infect Dis J.201635(3):263\u2013268."},{"issue":"3","key":"i1551-6776-25-6-472-b16","series-title":"Clin Infect Dis","first-page":"448","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","year":"2004","unstructured":"Charles\n              PG\n            , WardPB, JohnsonPD, \n          et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448\u2013451."},{"issue":"1","key":"i1551-6776-25-6-472-b17","series-title":"Clin Infect Dis","first-page":"51","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","year":"2012","unstructured":"Moore\n              CL\n            , Osaki-KiyanP, HaqueNZ, \n          et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51\u201358."},{"issue":"6","key":"i1551-6776-25-6-472-b18","series-title":"Pediatrics","doi-asserted-by":"publisher","first-page":"e20170183","DOI":"10.1542\/peds.2017-0183","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"139","year":"2017","unstructured":"Hamdy\n              RF\n            , HsuAJ, StockmannC, \n          et al. Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children. Pediatrics. 2017;139(6):e20170183. doi:10.1542\/peds.2017-0183"},{"issue":"1","key":"i1551-6776-25-6-472-b19","series-title":"Paediatr Drugs","first-page":"59","article-title":"Identifying high-risk medications associated with acute kidney injury in critically ill patients: a pharmacoepidemiologic evaluation","volume":"19","year":"2017","unstructured":"Slater\n              MB\n            , GruneirA, RochonPA, \n          et al. Identifying high-risk medications associated with acute kidney injury in critically ill patients: a pharmacoepidemiologic evaluation. Paediatr Drugs. 2017;19(1):59\u201367."},{"issue":"6","key":"i1551-6776-25-6-472-b20","series-title":"Pharmacotherapy","first-page":"598","article-title":"Acute kidney injury during vancomycin therapy in critically ill children","volume":"33","year":"2013","unstructured":"Totapally\n              BR\n            , MachadoJ, LeeH, \n          et al. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33(6):598\u2013602."},{"issue":"3","key":"i1551-6776-25-6-472-b21","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F236","article-title":"A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates","volume":"101","year":"2016","unstructured":"Constance\n              JE\n            , BalchAH, StockmannC, \n          et al. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed. 2016;101(3):F236\u2013F243."},{"issue":"1","key":"i1551-6776-25-6-472-b22","series-title":"N Engl J Med","first-page":"11","article-title":"Epidemiology of acute kidney injury in critically ill children and young adults","volume":"376","year":"2017","unstructured":"Kaddourah\n              A\n            , BasuRK, BagshawSM, \n          et al. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med. 2017;376(1):11\u201320."},{"issue":"12","key":"i1551-6776-25-6-472-b23","series-title":"Ann Pharmacother","first-page":"1555","article-title":"Factors associated with acute kidney injury in children receiving vancomycin","volume":"48","year":"2014","unstructured":"Sinclair\n              EA\n            , YenokyanG, McMunnA, \n          et al. Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother. 2014;48(12):1555\u20131562."},{"issue":"4","key":"i1551-6776-25-6-472-b24","series-title":"J Pediatric Infect Dis Soc","first-page":"e109","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children","volume":"4","year":"2015","unstructured":"Le\n              J\n            , NyP, CapparelliE, \n          et al. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. J Pediatric Infect Dis Soc. 2015;4(4):e109\u2013e116."},{"issue":"10","key":"i1551-6776-25-6-472-b25","series-title":"JAMA Pediatrics","first-page":"979","article-title":"The epidemiology and mortality of Staphylococcus aureus bacteremia in a prospective cohort of Australian and New Zealand children","volume":"170","year":"2016","unstructured":"McMullan\n              BJ\n            , BowenAC, BlythCC, \n          et al. The epidemiology and mortality of Staphylococcus aureus bacteremia in a prospective cohort of Australian and New Zealand children. JAMA Pediatrics. 2016;170(10):979\u2013986."},{"issue":"4","key":"i1551-6776-25-6-472-b26","series-title":"Pediatrics","doi-asserted-by":"publisher","first-page":"e20153099","DOI":"10.1542\/peds.2015-3099","article-title":"Changing susceptibility of Staphylococcus aureus in a US pediatric population","volume":"137","year":"2016","unstructured":"Sutter\n              DE\n            , MilburnE, ChukwumaU, \n          et al. Changing susceptibility of Staphylococcus aureus in a US pediatric population. Pediatrics. 2016;137(4):e20153099. doi:10.1542\/peds.2015-3099"},{"issue":"10","key":"i1551-6776-25-6-472-b27","series-title":"Infect Control Hosp Epidemiol","first-page":"1226","article-title":"S. aureus infections in Chicago, 2006\u20132014: increase in CA MSSA and decrease in MRSA incidence","volume":"38","year":"2017","unstructured":"Acree\n              ME\n            , MorganE, DavidMZ.\n          S. aureus infections in Chicago, 2006\u20132014: increase in CA MSSA and decrease in MRSA incidence. Infect Control Hosp Epidemiol. 2017;38(10):1226\u20131234."},{"issue":"3","key":"i1551-6776-25-6-472-b28","series-title":"Pediatr Infect Dis J","first-page":"235","article-title":"Analysis of invasive community-acquired methicillin-susceptible Staphylococcus aureus infections during a period of declining CA-MRSA infections at a large children\u2019s hospital","volume":"37","year":"2018","unstructured":"Hulten\n              KG\n            , MasonEO, LamberthLB, \n          et al. Analysis of invasive community-acquired methicillin-susceptible Staphylococcus aureus infections during a period of declining CA-MRSA infections at a large children\u2019s hospital. Pediatr Infect Dis J. 2018;37(3):235\u2013241."},{"issue":"5","key":"i1551-6776-25-6-472-b29","series-title":"Antimicrob Agents Chemother","first-page":"e00084","article-title":"Association of vancomycin MIC and molecular characteristics with clinical outcomes in methicillin-susceptible Staphylococcus aureus acute hematogenous osteoarticular infections in children","volume":"62","year":"2018","unstructured":"Kok\n              EY\n            , VallejoJG, SommerLM, \n          et al. Association of vancomycin MIC and molecular characteristics with clinical outcomes in methicillin-susceptible Staphylococcus aureus acute hematogenous osteoarticular infections in children. Antimicrob Agents Chemother. 2018;62(5):e00084\u201300018."},{"key":"i1551-6776-25-6-472-b30","series-title":"J Pediatric Infect Dis Soc.","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz036","article-title":"Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement [published online ahead of print July 25, 2019]","unstructured":"Olson\n              J\n            , HershAL, SorensenJ, \n          et al. Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement [published online ahead of print July 25, 2019]. J Pediatric Infect Dis Soc.doi:10.1093\/jpids\/piz036"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/6\/article-p472.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/25\/6\/472\/2585550\/1551-6776-25_6_472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/6\/article-p472.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/6\/article-p472.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:38:53Z","timestamp":1747355933000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/6\/article-p472.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":30,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-25.6.472","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}